Lmcg Investments LLC Has $8.10 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Lmcg Investments LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 105.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,836 shares of the company's stock after buying an additional 25,087 shares during the period. Lmcg Investments LLC's holdings in Johnson & Johnson were worth $8,099,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. MRP Capital Investments LLC boosted its stake in shares of Johnson & Johnson by 4.1% in the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock valued at $237,000 after purchasing an additional 65 shares during the period. Syverson Strege & Co raised its holdings in shares of Johnson & Johnson by 4.9% during the fourth quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares during the period. Werba Rubin Papier Wealth Management raised its holdings in shares of Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock worth $301,000 after purchasing an additional 66 shares during the period. Denali Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after purchasing an additional 67 shares during the period. Finally, Sage Mountain Advisors LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on JNJ. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America dropped their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and raised their target price for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Stock Up 0.9%

JNJ traded up $1.36 on Friday, reaching $155.02. 5,387,625 shares of the company traded hands, compared to its average volume of 7,950,051. The stock's 50 day moving average price is $153.59 and its 200-day moving average price is $153.67. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a market cap of $372.99 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.35%. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.